{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:45:03Z","timestamp":1788860703348,"version":"build-2803163510"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Multidrug-resistant tuberculosis (MDR-TB) is a global public health threat associated with high mortality and challenging treatment regimens. The UK, like many countries, faces a growing incidence of MDR-TB, with 105 (1.9% of all notified cases) treated as MDR-resistant or rifampicin-resistant TB in 2024. Recent clinical trials have demonstrated the efficacy and safety of shorter, all-oral regimens such as BPaLM (bedaquiline, pretomanid, linezolid, moxifloxacin), yet their implementation in the UK presents unique challenges, particularly around the antimicrobial stewardship (AMS) agenda, such as the lack of licensed drugs, pharmacokinetic\/dynamic concerns, fragile supply chains and high cost of second-line antituberculosis drugs. This narrative review outlines how the UK has addressed implementation hurdles through coordinated efforts by the British Thoracic Society MDR-TB Clinical Advice Service and National Health Service England. This collaboration has facilitated the adoption of new regimens, with 54 out of 60 requests for using pretomanid-containing regimens approved in the UK up to January 2026. Furthermore, resources like the TB Drug Monographs and the shift to video-observed therapy have streamlined care delivery. The UK has effectively navigated the transition to shorter, all-oral MDR-TB regimens, significantly enhancing patient care and operational efficiency. The integration of clinical guidance, AMS principles, policy reform and specialised monitoring tools provides a robust framework for managing evolving treatment landscapes and delivering patient-centred care.<\/jats:p>","DOI":"10.1136\/bmjresp-2025-003861","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:15:29Z","timestamp":1775146529000},"page":"e003861","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2852-6109","authenticated-orcid":false,"given":"Aneeka","family":"Chavda","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gilchrist","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London, London, UK"},{"name":"Department of Infectious Diseases and Microbiology, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9686-3067","authenticated-orcid":false,"given":"Toby","family":"Capstick","sequence":"additional","affiliation":[{"name":"Medicines Management and Pharmacy Services, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christabelle","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2647-4688","authenticated-orcid":false,"given":"Onn Min","family":"Kon","sequence":"additional","affiliation":[{"name":"Chest and Allergy Clinic, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2026040209151790000_13.1.e003861.1","unstructured":"World Health Organization . Global tuberculosis report, 2024. Geneva, 2024."},{"key":"2026040209151790000_13.1.e003861.2","unstructured":"Global strategy and targets for tuberculosis prevention, care and control after 2015 (resolution wha67.1, agenda item 12.1). Geneva World Health Assembly; 2014. Available: http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA67\/A67_R1-en.pdf"},{"key":"2026040209151790000_13.1.e003861.3","unstructured":"UK Health Security Agency . Tuberculosis in england, 2025 report. UKHSA; 2025. Available: https:\/\/www.gov.uk\/government\/publications\/tuberculosis-in-england-2025-report"},{"key":"2026040209151790000_13.1.e003861.4","doi-asserted-by":"crossref","unstructured":"Menzies NA , Allwood BW , Dean AS , et al . Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nat Commun 2023;14. doi:10.1038\/s41467-023-41937-9","DOI":"10.1038\/s41467-023-41937-9"},{"key":"2026040209151790000_13.1.e003861.5","doi-asserted-by":"crossref","unstructured":"Chung-Delgado K , Guillen-Bravo S , Revilla-Montag A , et al . Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One 2015;10. doi:10.1371\/journal.pone.0119332","DOI":"10.1371\/journal.pone.0119332"},{"key":"2026040209151790000_13.1.e003861.6","unstructured":"World Health Organization (WHO) . WHO consolidated guidelines on tuberculosis module 4: treatment drug-resistant tuberculosis treatment. Geneva, WHO; 2020."},{"key":"2026040209151790000_13.1.e003861.7","doi-asserted-by":"crossref","unstructured":"Ahuja SD , Ashkin D , Avendano M , et al . Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9. doi:10.1371\/journal.pmed.1001300","DOI":"10.1371\/journal.pmed.1001300"},{"key":"2026040209151790000_13.1.e003861.8","unstructured":"World Health Organisation . WHO consolidated guidelines on tuberculosis. module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022."},{"key":"2026040209151790000_13.1.e003861.9","unstructured":"World Health Organization . Key updates to the treatment of drug-resistant tuberculosis: rapid communication, june 2024. WHO; 2024."},{"key":"2026040209151790000_13.1.e003861.10","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: World Health Organization; 2025."},{"key":"2026040209151790000_13.1.e003861.11","unstructured":"National Institute for Health and Care Excellence (NICE) . Tuberculosis (nice guideline ng33). n.d. Available: https:\/\/www.nice.org.uk\/guidance\/ng33"},{"key":"2026040209151790000_13.1.e003861.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2026040209151790000_13.1.e003861.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2026040209151790000_13.1.e003861.14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang\u2019wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026040209151790000_13.1.e003861.15","doi-asserted-by":"crossref","unstructured":"Conradie F , Badat T , Poswa A , et al . BEAT tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis. Infectious Diseases (except HIV\/AIDS) [Preprint] 2025. doi:10.1101\/2025.05.04.25326549","DOI":"10.1101\/2025.05.04.25326549"},{"key":"2026040209151790000_13.1.e003861.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811867"},{"key":"2026040209151790000_13.1.e003861.17","unstructured":"World Health Organization . WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019."},{"key":"2026040209151790000_13.1.e003861.18","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"2026040209151790000_13.1.e003861.19","doi-asserted-by":"crossref","unstructured":"Guglielmetti L , Khan U , Vel\u00e1squez GE , et al . Oral Regimens for Rifampin-Resistant. 2025;392:468\u201382. doi:10.1056\/NEJMoa2400327","DOI":"10.1056\/NEJMoa2400327"},{"key":"2026040209151790000_13.1.e003861.20","doi-asserted-by":"crossref","unstructured":"Walker TM , Choisy M , Dedicoat M , et al . Mycobacterium tuberculosis transmission in Birmingham, UK, 2009-19: An observational study. Lancet Reg Health Eur 2022;17. doi:10.1016\/j.lanepe.2022.100361","DOI":"10.1016\/j.lanepe.2022.100361"},{"key":"2026040209151790000_13.1.e003861.21","unstructured":"British Thoracic Society . Available from. BTS mdr-tb clinical advice service annual report 2024. London British Thoracic Society; 2024. Available: https:\/\/www.brit-thoracic.org.uk\/document-library\/quality-improvement\/mdrtb\/bts-mdr-tb-clinical-advice-service-annual-report-2024\/"},{"key":"2026040209151790000_13.1.e003861.22","unstructured":"NHS England . Clinical commissioning policy: bpalm\/bpal for patients aged \u226514 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-xdr) tb [urn: 2310]. London: NHS England; 2024. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2024\/06\/2310-BPaLM-clinical-commissioning-policy-statement-June-2024.pdf"},{"key":"2026040209151790000_13.1.e003861.23","unstructured":"NHS England . Treatment for defined patients with rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB, pre-extensively drug-resistant (pre-XDR) TB and extensively drug-resistant (XDR-TB) including bedaquiline and delamanid (All Ages). London: NHS England; 2024. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2024\/06\/2317-bedaquiline-and-delamanid-clinical-commissioning-policy-statement.pdf"},{"key":"2026040209151790000_13.1.e003861.24","unstructured":"TB Drug Monographs . 2024. Available: https:\/\/www.tbdrugmonographs.co.uk"},{"key":"2026040209151790000_13.1.e003861.25","doi-asserted-by":"crossref","unstructured":"Borisov S , et al . World Health Organisation. Active tuberculosis drug-safety monitoring and management (aDSM): Framework for implementation. Eur Respir J 2015;54. doi:10.1183\/13993003.01522-2019%5D","DOI":"10.1183\/13993003.01522-2019"},{"key":"2026040209151790000_13.1.e003861.26","unstructured":"Medicines Health Regulatory Authority (MHRA) . Supply unlicensed medicinal products (specials). GOV.UK. n.d. Available: https:\/\/www.gov.uk\/government\/publications\/supply-unlicensed-medicinal-products-specials"},{"key":"2026040209151790000_13.1.e003861.27","unstructured":"Department of Health and Social Care (DHSC), NHS England . National patient safety alert: shortage of antimicrobial agents used in tuberculosis (tb) treatment. national patient safety alert reference number: natpsa\/2025\/004\/mva. 2025. Available: https:\/\/www.cas.mhra.gov.uk\/ViewandAcknowledgment\/ViewAlert.aspx?AlertID=103267"},{"key":"2026040209151790000_13.1.e003861.28","doi-asserted-by":"crossref","unstructured":"Sweeney S , Berry C , Kazounis E , et al . Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis. PLOS Glob Public Health 2022;2. doi:10.1371\/journal.pgph.0001337","DOI":"10.1101\/2022.11.08.22282060"},{"key":"2026040209151790000_13.1.e003861.29","unstructured":"National health service (charges to overseas visitors) regulations 2015. 2015. Available: https:\/\/www.legislation.gov.uk\/uksi\/2015\/238"},{"key":"2026040209151790000_13.1.e003861.30","unstructured":"Department of Health and Social Care . TB action plan for England 2021-2026. London: DHSC; 2021. Available: https:\/\/www.gov.uk\/government\/publications\/tuberculosis-tb-action-plan-for-england\/tuberculosis-tb-action-plan-for-england-2021-to-2026"},{"key":"2026040209151790000_13.1.e003861.31","unstructured":"UK Health Security Agency. Tackling TB in inclusion health groups: a toolkit for a multi-agency approach, 2024. Available: https:\/\/www.gov.uk\/government\/publications\/tackling-tb-in-inclusion-health-groups-toolkit-for-a-multi-agency-approach\/tackling-tb-in-inclusion-health-groups-a-toolkit-for-a-multi-agency-approach#references"},{"key":"2026040209151790000_13.1.e003861.32","unstructured":"Rx-info. Available: https:\/\/rxinfo.thirdparty.nhs.uk\/ [Accessed 3 Aug 2025]."}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:15:33Z","timestamp":1775146533000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,2]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjresp-2025-003861"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003861","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}